ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
- Conditions
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06373731
- Locations
- ๐ฌ๐ง
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
๐บ๐ธAssociated Retina Consultants, Phoenix, Arizona, United States
๐บ๐ธBarnet Dulaney Perkins Eye Center, Sun City, Arizona, United States
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT05162768
- Locations
- ๐บ๐ธ
Rare Disease Research, LLC, Atlanta, Georgia, United States
๐บ๐ธUniversity of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics, Pittsburgh, Pennsylvania, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
An Intermediate Size Expanded Access Protocol of Elamipretide
- Conditions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Registration Number
- NCT04689360
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03891875
- Locations
- ๐บ๐ธ
The Retina Care Center, Baltimore, Maryland, United States
๐บ๐ธSoutheast Retina Center, PC, Augusta, Georgia, United States
๐บ๐ธCumberland valley retina consultants, Hagerstown, Maryland, United States
A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
- Conditions
- Interventions
- First Posted Date
- 2017-10-27
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT03323749
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
๐บ๐ธUniversity of Texas Health Science Center, Houston, Texas, United States
A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03098797
- Locations
- ๐บ๐ธ
McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)
- Conditions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 215
- Registration Number
- NCT03048617
- Locations
- ๐บ๐ธ
University of California San Diego, La Jolla, California, United States
๐ฉ๐ชKlinikim der Universitat Muchen, Friedrich-Baur Institute, Munich, Bavaria, Germany
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02976038
- Locations
- ๐บ๐ธ
University of California, San Diego, California, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 308
- Registration Number
- NCT02914665
- Locations
- ๐ฌ๐ง
Torbay Hospital, Torquay, United Kingdom
๐ช๐ธHospital Clรญnico San Carlos, Madrid, Spain
๐ช๐ธHospital Universitario de Bellvitge, Barcelona, Spain
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02848313
- Locations
- ๐บ๐ธ
Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center), Durham, North Carolina, United States